Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its price objective decreased by investment analysts at JPMorgan Chase & Co. from $10.00 to $8.00 in a report issued on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 26.98% from the […]
Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) posted its quarterly earnings results on Sunday. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.32 by $1.02, MarketWatch Earnings reports. Atea Pharmaceuticals had a return on equity of 20.59% and a net margin of 34.49%. NASDAQ AVIR opened at $6.46 on […]
Atea Pharmaceuticals (NASDAQ:AVIR – Get Rating) had its target price decreased by equities researchers at SVB Leerink from $10.00 to $9.00 in a report issued on Tuesday, Stock Target Advisor reports. The firm presently has a “market perform” rating on the stock. SVB Leerink’s price objective points to a potential upside of 41.96% from the […]
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year Low After Analyst Downgrade etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.